Immunoforge specializes in novel drug development with pipelines based on half-life extension platform technology.
Identification | Indication | Target | Discovery | Non-clinical | Phase I | Phase II | Comments | |
---|---|---|---|---|---|---|---|---|
ELP Platform |
Froniglutide | Dermatomyositis (DM)/ Polymyositis (PM) |
GLP-1R* (Weekly) * Sarcopenia |
|
FDA, MFDS ODD |
|||
Duchenne Muscular Dystrophy (DMD) |
|
FDA ODD | ||||||
Inclusion Body Myositis (IBM) |
|
|||||||
Senile Sarcopenia |
|
|||||||
Pemziviptadil | Cardiomyopathy(DMD), Heart Failure, Cystic Fibrosis |
VPAC2 |
|
FDA ODD | ||||
PF1805 | Achondroplasia | NPR-B (Weekly) |
|
|||||
PF1806 | Short Bowel Syndrome (SBS) | GLP-2R (Weekly) |
|
|||||
PF1807 | Sarcopenia | GLP-1R (Monthly) |
|
|||||
PF1808 | L/O |
|
||||||
PF1802 | Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease |
Bifunctional |
|
|||||
PF1803 | Osteoarthritis (OA) | Bifunctional OSCAR + |
|
|||||
KF1601 | Drug Resistant Chronic Myeloid Leukemia (CML) |
BCR-ABL1 (T315I) |
|
FDA ODD |